AVITA Medical Inc (ASX: AVH) Share Price and News

Price

$2.76

Movement

0.06 (-2.13%)

As at 22 Jan 2:10pm (20 mins delayed)

52 Week Range

$2.34 - $5.62

 
1 Year Return

-40.39%

AVITA Medical Inc Chart and Price Data

2025
2025
2025
2025
$2
$4
$6
$2
$4
$6
$2
$4
$6
$2
$4
$6

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $371.33 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 131.09 million
Earnings per share -0.446
Dividend per share N/A
Year To Date Return -34.12%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-34.12%

Shares Outstanding

131.09 million

Earnings per share

-0.446

Share Price

$2.76

Day Change

0.06 (-2.13%)

52 Week Range

$2.34 - $5.62

Yesterday's Close

$2.82

Today's Open

$2.82

Days Range

$2.75 - $2.84

Volume

183,687

Avg. Volume (1 month)

522,712

Turnover

$509,032

As at 22 Jan 2:10pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    happy investor, share price rise, increase, up
    Small Cap Shares

    Broker says these exciting small cap ASX shares have massive upside

    Check out these highly rated small cap ASX shares with major upside potential.

    Read more »

    A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.
    Healthcare Shares

    Here's why the Avita Medical share price is tumbling 20% today

    Shares in the healthcare company are tanking today, despite no fresh news out since last week.

    Read more »

    A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
    Share Gainers

    5 top ASX shares that would have more than doubled your money in 2023

    Investing in ASX shares has been a profitable venture for most investors in 2023. Especially investors who snapped up shares…

    Read more »

    An excited man stretches his arms out above his head as he reaches a mountain peak representing two ASX 200 shares reaching multi-year high prices today
    52-Week Highs

    7 ASX All Ordinaries shares smashing new 52-week highs today

    These shares are making investors very happy this Thursday.

    Read more »

    doctor with wide open mouth as if expressing surprise at rising avita share price
    Share Gainers

    Guess which ASX All Ordinaries stock has soared 50% in 3 days after reporting

    Here's why investors in this company have become a lot richer this week.

    Read more »

    A graphic image of three upward pointing arrows with smoke coming from their bottoms, indicating the arrows are taking off just like the Althea share price today
    Share Gainers

    3 ASX All Ordinaries shares that defied today's sell-off to leap higher

    We take a look at what's going on with these three ASX All Ordinaries shares.

    Read more »

    Happy healthcare workers in a labs
    Healthcare Shares

    Is there an $8 billion 'pot of gold at the end of the rainbow' for investors in this ASX healthcare share?

    It's been a rough few years for Avita shareholders.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Ask a Fund Manager

    2 absolute bargain ASX shares to buy right now: analyst

    Ask A Fund Manager: Bell Direct's Grady Wulff examines three stocks that have plunged this year to see if they're…

    Read more »

    a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
    Share Gainers

    3 ASX All Ordinaries shares defying today's rout to surge higher

    These ASX All Ords shares are bucking today's sell-off.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Earnings Results

    Avita share price dives 16% on net loss

    The medical technology company's shares are falling following today's financial results

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Share Gainers

    Why is the Avita Medical share price tracking 20% higher today?

    Shares in the regenerative medicine company continue their gains, tracking higher over the past month.

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    Bell Potter names 2 of the best ASX healthcare shares to buy in FY23

    These healthcare shares could be buys for FY 2023...

    Read more »

    Frequently Asked Questions

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    9th Jan 2025 2025-01-09T09:45:27 Notice under section 708A(5)(e) of the Corporations ActYesNo9:45am2156k
    9th Jan 2025 2025-01-09T09:43:17 Notification regarding unquoted securities - AVHYesNo9:43am818k
    8th Jan 2025 2025-01-08T16:28:58 Statement of CDIs on issue - AVHYesNo4:28pm722k
    8th Jan 2025 2025-01-08T10:26:41 Notice under section 708A(5)(e) of the Corporations ActYesNo10:26am2156k
    8th Jan 2025 2025-01-08T10:21:31 Notification regarding unquoted securities - AVHYesNo10:21am921k
    8th Jan 2025 2025-01-08T10:06:16 Notification of cessation of securities - AVHYesNo10:06am718k
    8th Jan 2025 2025-01-08T09:13:21 AVH Updates Expected Q4 & FY24 Revenue, FY25 GuidanceYesNo9:13am3159k
    27th Dec 2024 2024-12-27T09:12:41 Notice under section 708A(5)(e) of the Corporations ActYesNo9:12am2163k
    27th Dec 2024 2024-12-27T09:10:51 Notification regarding unquoted securities - AVHYesNo9:10am818k
    24th Dec 2024 2024-12-24T08:21:12 AVITA Medical Announces FDA Approval of RECELL GO miniYesNo8:21am2234k

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jan 2025 $2.84 $0.04 1.43% 350,923 $2.80 $2.85 $2.74
    17 Jan 2025 $2.80 $-0.06 -2.10% 508,782 $2.82 $2.83 $2.74
    16 Jan 2025 $2.86 $0.00 0.00% 245,622 $2.92 $2.92 $2.85
    15 Jan 2025 $2.86 $-0.04 -1.38% 234,783 $2.87 $2.93 $2.85
    14 Jan 2025 $2.90 $-0.09 -3.01% 442,645 $2.94 $2.95 $2.85
    13 Jan 2025 $2.99 $-0.07 -2.29% 531,540 $3.04 $3.04 $2.96
    10 Jan 2025 $3.06 $0.01 0.33% 692,206 $3.06 $3.15 $3.05
    09 Jan 2025 $3.05 $-0.46 -13.11% 1,918,273 $2.95 $3.15 $2.89
    08 Jan 2025 $3.51 $-0.84 -19.31% 2,205,923 $3.92 $3.92 $3.47
    07 Jan 2025 $4.35 $0.09 2.11% 115,722 $4.31 $4.40 $4.30
    06 Jan 2025 $4.26 $0.12 2.90% 241,904 $4.19 $4.33 $4.16
    03 Jan 2025 $4.14 $-0.03 -0.72% 110,103 $4.19 $4.21 $4.11
    02 Jan 2025 $4.17 $-0.08 -1.88% 122,185 $4.16 $4.20 $4.08
    31 Dec 2024 $4.25 $-0.12 -2.75% 152,104 $4.28 $4.31 $4.17
    30 Dec 2024 $4.37 $-0.02 -0.46% 237,410 $4.45 $4.52 $4.30
    27 Dec 2024 $4.39 $0.45 11.42% 741,139 $4.16 $4.42 $4.16
    24 Dec 2024 $3.94 $0.13 3.41% 756,731 $4.05 $4.11 $3.94

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Jun 2024 Louis (Lou) Panaccio Exercise 6,175 $17,660
    Conversion of securities. 9,200 Rights
    07 Jun 2024 Louis (Lou) Panaccio Issued 6,175 $17,660
    Conversion of securities.
    07 Jun 2024 Suzanne Crowe Issued 6,175 $17,660
    Conversion of securities.
    07 Jun 2024 Suzanne Crowe Exercise 6,175 $17,660
    Conversion of securities. 9,200 RSU
    07 Jun 2024 Jeremy Curnock-Cook Issued 6,175 $17,660
    Conversion of securities.
    07 Jun 2024 Jeremy Curnock-Cook Exercise 6,175 $17,660
    Conversion of securities. 9,200 RSU
    07 Jun 2024 Jan Reed Exercise 6,175 $17,660
    Conversion of securities. 12,091 RSU
    07 Jun 2024 Jan Reed Issued 6,175 $17,660
    Conversion of securities.
    07 Jun 2024 Cary Vance Issued 9,633 $27,550
    Conversion of securities.
    07 Jun 2024 Cary Vance Exercise 9,633 $27,550
    Conversion of securities. 16,116 Rights
    07 Jun 2024 Robert McNamara Exercise 9,633 $27,550
    Conversion of securities. 16,116 RSUs
    07 Jun 2024 Robert McNamara Issued 9,633 $27,550
    Conversion of securities.
    06 Jun 2024 Louis (Lou) Panaccio Issued 9,200 $26,036
    Issue of securities. 15,375 RSU
    06 Jun 2024 Louis (Lou) Panaccio Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 Robert McNamara Issued 9,200 $26,036
    Issue of securities. 25,749 RSU
    06 Jun 2024 Robert McNamara Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 James Corbett Issued 350,000 $990,500
    Issue of options.
    06 Jun 2024 Cary Vance Issued 9,200 $26,036
    Issue of securities. 25,749 RSU
    06 Jun 2024 Cary Vance Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 Jan Reed Issued 9,200 $26,036
    Issue of securities. 18,266 RSU
    06 Jun 2024 Jan Reed Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 Jeremy Curnock-Cook Issued 9,200 $26,036
    Issue of securities. 15,375 RSU
    06 Jun 2024 Jeremy Curnock-Cook Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 Suzanne Crowe Issued 3,943 $11,158
    Issue of options.
    06 Jun 2024 Suzanne Crowe Issued 9,200 $26,036
    Issue of securities. 15,375 RSU

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Louis (Lou) James Panaccio Non-Executive ChairmanNon-Executive Director Jul 2014
    Mr Panaccio is a healthcare businessman with experience leading companies from concept to commercialization. Mr. Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr Panaccio is currently a Director of ASX50 company and one of the medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005.
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Director of Sonic Healthcare Ltd, a global medical diagnostics company. Past board positions include St Vincent's Health Australia Ltd (2012-2021), the country's not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Curnock-Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr Curnock Cook has managed more than US $1bn in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and investor in the sector. In his early career he founded the International Biochemicals Group which he sold to Royal Dutch Shell.
    Dr Michael S Perry Chief Executive Officer Feb 2013
    Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr Cary Vance Non-Executive Director Apr 2023
    Mr Vance has over 25 years of leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of PhotoniCare, Inc., a position he has held since May 2023. Prior to this appointment, he was President and CEO of Titan Medical, and he continues to serve as an independent director for Titan Medical's Board of Directors. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine.
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Mr James Corbett Chief Executive OfficerPresident Jul 2021
    -
    Ms Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary Jul 2024
    -
    James Corbett Chief Executive OfficerPresident
    -
    David O'Toole Chief Financial Officer
    -
    Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary
    -
    Mark Andrew Licciardo Company Secretary
    -
    Donna Shiroma General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    UBS Nominees Pty Ltd 417,970 1.63%
    Citicorp Nominees Pty Limited 400,634 1.56%
    Washington H Soul Pattinson And Company Limited 302,529 1.18%
    BNPP Noms Pty Ltd HUB24 Custodial Serv Ltd 285,593 1.11%
    P Morgan Nominees Australia Pty Limited 204,641 0.80%
    Mr Evan Philip Clucas and Ms Leanne Jane Weston Kuranga Nursery Super A/C> 159,013 0.62%
    Hsbc Custody Nominees (Australia) Limited 122,390 0.48%
    Merrill Lynch (Australia) Nominees Pty Limited 97,530 0.38%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 92,521 0.36%
    Bnp Paribas Noms Pty Ltd 90,998 0.35%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 85,911 0.33%
    Taggart Investments Pty Ltd <Taggart Investment A/C> 76,800 0.30%
    Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 63,116 0.25%
    Mr Eduard Avetisov 62,060 0.24%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 61,873 0.24%
    Mr Andre Wall Ellis and Mrs Olivia Louise Ellis 60,000 0.23%
    Mrs Arlene Perry 60,000 0.23%
    Wairahi Investments Limited 60,000 0.23%
    Sandhurst Trustees Ltd <Jmfg Consol A/C> 55,740 0.22%
    Mr David Anthony Deelen 50,800 0.20%

    Profile

    since

    Note